1. Koska J, Stefan N, Permana PA, Weyer C, Sonoda M, Bogardus C, Smith SR, Joanisse DR, Funahashi T, Krakoff J, Bunt JC. Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, visceral adiposity, and hypoadiponectinemia in obese individuals. Am J Clin Nutr. 2008; 87:295–302.
2. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006; 580:2917–2921.
3. Doan DD, Nguyen NH, Doan HK, Nguyen TL, Phan TS, van Dau N, Grabe M, Johansson R, Lindgren G, Stjernström NE. Studies on the individual and combined diuretic effects of four Vietnamese traditional herbal remedies (Zea mays, Imperata cylindrica, Plantago major and Orthosiphon stamineus). J Ethnopharmacol. 1992; 36:225–231.
4. Hasanudin K, Hashim P, Mustafa S. Corn silk (Stigma maydis) in healthcare: a phytochemical and pharmacological review. Molecules. 2012; 17:9697–9715.
5. Kan A, Orhan I, Coksari G, Sener B. In-vitro neuroprotective properties of the Maydis stigma extracts from four corn varieties. Int J Food Sci Nutr. 2012; 63:1–4.
6. Velazquez DV, Xavier HS, Batista JE, de Castro-Chaves C. Zea mays L. extracts modify glomerular function and potassium urinary excretion in conscious rats. Phytomedicine. 2005; 12:363–369.
7. Zhao W, Yin Y, Yu Z, Liu J, Chen F. Comparison of anti-diabetic effects of polysaccharides from corn silk on normal and hyperglycemia rats. Int J Biol Macromol. 2012; 50:1133–1137.
8. Farsi DA, Harris CS, Reid L, Bennett SA, Haddad PS, Martineau LC, Arnason JT. Inhibition of non-enzymatic glycation by silk extracts from a Mexican land race and modern inbred lines of maize (Zea mays). Phytother Res. 2008; 22:108–112.
9. Suzuki R, Okada Y, Okuyama T. The favorable effect of style of Zea mays L. on streptozotocin induced diabetic nephropathy. Biol Pharm Bull. 2005; 28:919–920.
10. Guo J, Liu T, Han L, Liu Y. The effects of corn silk on glycaemic metabolism. Nutr Metab (Lond). 2009; 6:47.
11. Maksimović Z, Dobrić S, Kovacević N, Milovanović Z. Diuretic activity of Maydis stigma extract in rats. Pharmazie. 2004; 59:967–971.
12. Bai H, Hai C, Xi M, Liang X, Liu R. Protective effect of maize silks (Maydis stigma) ethanol extract on radiation-induced oxidative stress in mice. Plant Foods Hum Nutr. 2010; 65:271–276.
13. Choi DJ, Kim SL, Choi JW, Park YI. Neuroprotective effects of corn silk maysin via inhibition of H2O2-induced apoptotic cell death in SK-N-MC cells. Life Sci. 2014; 109:57–64.
14. Maksimović Z, Malencić D, Kovacević N. Polyphenol contents and antioxidant activity of Maydis stigma extracts. Bioresour Technol. 2005; 96:873–877.
15. Kim SL, Kim MJ, Lee YY, Jung GH, Son BY, Lee JS, Kwon YU, Park YI. Isolation and identification of flavonoids from corn silk. Korean J Crop Sci. 2014; 59:435–444.
16. Waiss AC Jr, Chan BG, Elliger CA, Wiseman BR, McMillian WW, Widstrom NW, Zuber MS, Keaster AJ. Maysin, a flavone glycoside from corn silks with antibiotic activity toward corn earworm. J Econ Entomol. 1979; 72:256–258.
17. Lee EA, Byrne PF, McMullen MD, Snook ME, Wiseman BR, Widstrom NW, Coe EH. Genetic mechanisms underlying apimaysin and maysin synthesis and corn earworm antibiosis in maize (Zea mays L.). Genetics. 1998; 149:1997–2006.
18. Jeong HW, Lee JW, Kim WS, Choe SS, Kim KH, Park HS, Shin HJ, Lee GY, Shin D, Lee H, Lee JH, Choi EB, Lee HK, Chung H, Park SB, Park KS, Kim HS, Ro S, Kim JB. A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma. Diabetes. 2011; 60:496–506.
19. Min OJ, Sharma BR, Park CM, Rhyu DY. Effect of myadis stigma water extract on adipogenesis and blood glucose in 3T3-L1 adipocytes and db/db mice. Korean J Pharmacogn. 2011; 42:201–208.
20. Schreyer SA, Wilson DL, LeBoeuf RC. C57BL/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis. Atherosclerosis. 1998; 136:17–24.
21. Reeves PG. Components of the AIN-93 diets as improvements in the AIN-76A diet. J Nutr. 1997; 127:838S–841S.
22. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957; 226:497–509.
23. Ha AW, Kim WK. The effect of fucoxanthin rich power on the lipid metabolism in rats with a high fat diet. Nutr Res Pract. 2013; 7:287–293.
24. Dai W, Wang K, Zheng X, Chen X, Zhang W, Zhang Y, Hou J, Liu L. High fat plus high cholesterol diet lead to hepatic steatosis in zebrafish larvae: a novel model for screening anti-hepatic steatosis drugs. Nutr Metab (Lond). 2015; 12:42.
25. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006; 116:1784–1792.
26. Li Y, Qin G, Liu J, Mao L, Zhang Z, Shang J. Adipose tissue regulates hepatic cholesterol metabolism via adiponectin. Life Sci. 2014; 118:27–33.
27. Liu Q, Yuan B, Lo KA, Patterson HC, Sun Y, Lodish HF. Adiponectin regulates expression of hepatic genes critical for glucose and lipid metabolism. Proc Natl Acad Sci U S A. 2012; 109:14568–14573.
28. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T. Globular adiponectin protected ob/ob mice from diabetes and ApoEdeficient mice from atherosclerosis. J Biol Chem. 2003; 278:2461–2468.
29. DeBose-Boyd RA. Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase. Cell Res. 2008; 18:609–621.
30. Krause BR, Pape ME, Kieft K, Auerbach B, Bisgaier CL, Homan R, Newton RS. ACAT inhibition decreases LDL cholesterol in rabbits fed a cholesterol-free diet. Marked changes in LDL cholesterol without changes in LDL receptor mRNA abundance. Arterioscler Thromb. 1994; 14:598–604.
31. Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: a look back and a look ahead. Can J Cardiol. 1992; 8:843–864.
32. Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler Thromb Vasc Biol. 1997; 17:2589–2600.
33. Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J Lipid Res. 1999; 40:1317–1327.
34. Llaverías G, Laguna JC, Alegret M. Pharmacology of the ACAT inhibitor avasimibe (CI-1011). Cardiovasc Drug Rev. 2003; 21:33–50.
35. Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez R, Vlasuk GP, Harnish DC. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol. 2009; 296:G543–G552.
36. Mencarelli A, Fiorucci S. FXR an emerging therapeutic target for the treatment of atherosclerosis. J Cell Mol Med. 2010; 14:79–92.